Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 8/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | GGT1 | P19440 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769044 | 1.00 | GFPT1 (0.49) | GFPT1SLC7A5CASRSLC1A3SLC1A2 | |
| SCHEMBL16316678 | 0.83 | ANPEP (0.34) | GFPT1SLC7A5CASR | |
| SCHEMBL16151143 | 0.82 | GFPT1 (0.45) | GFPT1SLC7A5CASRSLC1A3SLC1A2 | |
| SCHEMBL22401380 | 0.82 | GFPT1 (0.45) | GFPT1SLC7A5CASRSLC1A3SLC1A2 | |
| SCHEMBL16151141 | 0.82 | GFPT1 (0.45) | GFPT1SLC7A5CASRSLC1A3SLC1A2 | |
| SCHEMBL28516179 | 0.82 | GFPT1 (0.45) | GFPT1SLC7A5CASRSLC1A3SLC1A2 | |
| SCHEMBL11652880 | 0.79 | ANPEP (0.37) | SLC7A5 | |
| SCHEMBL1768888 | 0.79 | GSR (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1GGT1 | |
| SCHEMBL1768887 | 0.79 | GSR (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1GGT1 | |
| SCHEMBL25345631 | 0.77 | GFPT1 (0.52) | GFPT1SLC7A5CASRSLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023014927-A1 | PRODRUGS OF TAPINAROF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-02-09 | — | — | WO | disclosed |
| US-9637520-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2017-05-02 | — | — | US | disclosed |
| EP-2531520-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2016-05-11 | — | — | EP | disclosed |
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9109009-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2015-08-18 | — | — | US | disclosed |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD (IE) | 2015-02-26 | — | — | US | disclosed |
| US-8937048-B2 | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2015-01-20 | — | — | US | disclosed |
| US-8912148-B2 | Methods of treating a disease or condition associated with abnormal angiogenesis | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2014-12-16 | — | — | US | disclosed |
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2013-08-29 | — | — | US | disclosed |
| EP-2531520-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | Polyphor AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD. | 2012-11-29 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-8293714-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-23 | — | — | US | disclosed |
| US-8288349-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-16 | — | — | US | disclosed |
| EP-2501715-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | Polyphor Ag (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011095607-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2010-01-07 | — | — | US | disclosed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, FLT1 | GFPT1 3413/4885SLC7A5 2288/4885CASR 2524/4885 |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | GFPT1 3069/4885SLC7A5 1767/4885CASR 469/4885 |
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | GFPT1 1208/4885SLC7A5 760/4885CASR 913/4885 |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | GFPT1 3289/4885SLC7A5 1749/4885CASR 1558/4885 |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, FLT4, TEK | GFPT1 3955/4885SLC7A5 2907/4885CASR 3000/4885 |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, TIE1, TEK | GFPT1 4076/4885SLC7A5 3334/4885CASR 3193/4885 |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | GFPT1 1167/4885SLC7A5 677/4885CASR 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.